Company Profile

C.R. Bard specializes in the design, manufacturing and marketing of medical supplies. The group offers medical, surgical, and diagnosis products (implantable chambers, probes, catheters, biopsy tools, etc.). Net sales break down by application area as follows: - vascular (27.3%); - oncology (27.3%); - urology (25.6%); - surgical specialties (17.2%); - other (2.6%). Net sales are distributed geographically as follows: the United States (68.9%), Asia/Pacific (13.2%), Europe (12%) and other (5.9%).

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

28/09/17	C R Bard : Becton Dickinson offers EU concessions over $24 billion Bard deal	RE
24/04/17	C R Bard : Becton Dickinson to acquire Bard for $24 billion	RE
15/10/16	C R Bard : Private equity firms line up bids for BSN Medical - sources	RE
09/07/16	Abbott Laboratories : Medtech's 2016 stock surge confronts second-quarter test	RE
19/05/16	Issue resolved at NYSE, some orders canceled: exchange	RE
15/10/14	Goldman Sachs : ConvaTec owners appoint banks to explore sale - sources	RE
17/04/13	C.R. Bard, Inc. : J&J tops estimates as prescription, OTC drugs shine	RE

30/12/17	C R Bard : BD Completes Bard Acquisition, Creating New Global Health Care Leader	PR
28/12/17	C R Bard : BD Statement On MOFCOM Clearance Of Bard Acquisition	PR
23/12/17	C R Bard : BD Statement On FTC Clearance Of Bard Acquisition	PR
16/11/17	C R Bard : BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines	PR
26/10/17	C R Bard : Bard Announces Third Quarter Results	BU

24/04/17	Abbott Laboratories : Milliarden-Übernahme in der amerikanischen Medizintechnik-Branche
24/04/17	USA/Equipements médicaux-Becton Dickinson rachète Bard pour $24 mds
15/10/16	Des fonds préparent des offres sur BSN Medical-sources
29/01/14	C.R. Bard, Inc. : Medikamentfreisetzender Lutonix Ballon und BTK-Studie von Bard auf der Agenda des Symposiums im Rahmen des Leipzig Interventional Course 2014

Manager	Title	Age	Since
Brooke Story CEO	Chief Executive Officer	-	-
Michael Hastings DFI	Director of Finance/CFO	83	-
Gary DeFazio LAW	General Counsel	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
C.R. BARD	-.--%	-0.05%	-	-	0
ABBOTT LABORATORIES	+0.95%	-0.99%	-33.56%	-11.36%	155B
MEDTRONIC PLC	+0.54%	-1.75%	-8.59%	-4.49%	103B
CENCORA, INC.	+0.49%	+4.75%	-1.21%	+57.91%	54.72B
HOYA CORPORATION	-0.23%	-6.71%	+50.66%	+49.87%	53.65B
BECTON, DICKINSON AND COMPANY	-0.15%	-1.42%	-14.64%	-41.20%	40.72B
MEDLINE INC.	+0.66%	+6.24%	-	-	30.9B
DEXCOM, INC.	+0.84%	+4.06%	-8.98%	-40.48%	28.85B
WEST PHARMACEUTICAL SERVICES, INC.	-0.14%	+4.23%	+47.65%	-7.46%	23.38B
TERUMO CORPORATION	-1.93%	-0.66%	-14.31%	+2.17%	21.22B
Average	+0.11%	+2.59%	+2.13%	+0.62%	56.87B
Weighted average by Cap.	+0.44%	+2.29%	-7.26%	+1.34%

C.R. Bard Stock

Stocks

BCR

US0673831097

Medical Equipment, Supplies & Distribution

Latest news : C.R. Bard

Press Releases: C.R. Bard

News in other languages: C.R. Bard

Managers and Directors: C.R. Bard

Other Medical Equipment, Supplies & Distribution

Company Profile